Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1
|
|
- Brendan Phillips
- 5 years ago
- Views:
Transcription
1 Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1 ASAHI KASEI CHEMICALS CORPORATION CEOLUS R&D DEPARTMENT 1
2 CONTENTS General Characteristics of SWELSTAR TM MX-1 Special Properties of SWELSTAR TM MX-1 Application Fields of SWELSTAR TM MX-1 Mechanism of Dissolution Control by SWELSTAR TM MX-1 Conclusions 2
3 General Characteristics of SWELSTAR TM MX-1 Developed by Asahi Kasei Chemicals and Sanwa Cornstarch. Produced by physical modification of potato starch. Performs as matrix agent to control sustained drug release. Applicable for CR of drugs with various water solubilities. Dissolution controllable tablets in different media. Conformable to USP/NF, EP and JPE [Pregelatinized Starch]. 3
4 Special Properties of SWELSTAR TM MX-1 Water soluble and insoluble elements - Resistant to alpha-amylase High swelling ability by rapid hydration - Gel matrix structure - Independent of ionic strength in test media Strong gel matrix structure having resistance to erosion - Resistant to digestive tract motions Controllable gel strength with addition of water soluble material - Dissolution control - Zero-order release profile Low reactivity - High storage stability 4
5 Powder Properties of SWELSTAR TM MX-1 Particle morphology a) Dry state (SEM) b) Wet state (OM *1 ) Typical properties of MX-1 Bulky density [g/cm 3.27 ] Repose angle [ ] 36 * 1 Optical microscope Av. particle diameter [μm] Water holding capacity [%] Swelling volume [cm 3 /g] Water soluble content [%] Viscosity [mpa s] 2% solution at 25 ºC MX-1 consists of water soluble and insoluble substances. The insoluble part keeps the raw starch-like crystalline structure, contributing to its resistance to alpha-amylase. MX-1 forms gel matrix structure after swelling by rapid hydration. 5
6 Application Fields of SWELSTAR TM MX-1 Controlled release gel-matrix tablets Dissolution control of direct compression tablets - various drugs with different water solubilities - various media with different ph - different rotation speeds - storage stability of the drug release profile 6
7 Dissolution Control of Direct Compression Tablets Purpose of this study Generally, dissolution profile of direct compression (DC) tablets is faster than that of wet-granulation (WG) tablets. Therefore, it is not easy to adjust the dissolution profile of DC tablets to that of WG tablets in various test media required by the guideline for the bioequivalence tests of generic drugs. It was investigated whether it is possible to adjust the dissolution profile of DC tablets in different test media by using a small amount of MX-1 to the original dissolution profile of WG tablets. 7
8 Benefits of DC Method WG method Powder Granulation and drying granule Tableting Tablet DC method Powder Tableting Tablet DC method has no granulation and drying process, therefore it can give an effective cost reduction. 8
9 Experiment Procedure - Highly Water Soluble Drug - WG method SSA 1 MCC 2 Lactose 3 CS 4 HPC-L 5 7 wt% 1 wt% 15 wt% 5 wt%.75 wt%* (*Of total of above) 1 Sodium salicylic acid, Yoshitomi (Solubility in water: 125 mg/ml) 2 Microcrystalline cellulose, Ceolus PH-11, ASAHI KASEI 3 Pharmatose 2M, DMV-Fonterra 4 Corn starch, ST-C, Nippon Starch Chemical 5 Hydroxypropyl cellulose, Type L Granulation Drying High shear granulator VG-1 (Powrex Corporation), Load: 16g, Binder: 2g (6% HPC-L aq.), Impeller: 28rpm, Cross screw: 3rpm, Granulation time: 3min Fluidized bed granulator MP-1 (Powrex Corporation) Granule 141 μm Tableting Single press (MODEL-1321DW CREEP, AIKOH Engineering) 18 mg, φ8 mm, round-face (Tablet hardness: about 6N) Evaluation Dissolution test Rotating paddle (5, 1 rpm) method with 9 ml medium: Water, Artificial gastric buffer ph 1.2 (1st fluid in JP XIV) and Artificial intestinal buffer ph 6.8 (2nd fluid in JP XIV) 9
10 Experiment Procedure - Highly Water Soluble Drug - SSA 1 MCC 2 Lactose 3 SiO2 4 DC-1 method 7 wt% 2 wt% 1 wt%.5 wt%* (*Of above total) SSA 1 MCC 2 Lactose 3 MX-1 or HPC-L 5 SiO2 4 DC-2 method 7 wt% 18-2 wt% -7 wt% 3-12 wt%.5 wt%* (*Of above total) 1 Sodium salicylic acid, Yoshitomi 2 Microcrystalline cellulose, Ceolus UF-711, ASAHI KASEI 3 Super-Tab TM, DMV-Fonterra 4 Silica, Aerosil 2, Nippon Aerosil 5 Hydroxypropyl cellulose, Type L Mixing for 3 min in PE bag Tableting Single press (MODEL-1321DW CREEP, AIKOH Engineering) 18 mg, φ8 mm, round-face (Tablet hardness: about 6N) Evaluation Dissolution test Rotating paddle (5, 1 rpm) method with 9 ml medium, Water, Artificial gastric buffer ph 1.2 (1st fluid in JP XIV) and Artificial intestinal buffer ph 6.8 (2nd fluid in JP XIV) 1
11 Dissolution Profiles from WG Tablets and DC Tablets - Highly Water Soluble Drug - 1 ph Buffer 1.2 直打処方 DC-1 Tablets 1 DC-2 Method Tablets (MX-1) DC-1 Tablets 直打処方 溶出率 時間 湿打処方 WG Tablets 溶出率 時間 [min] DC-2 Tablets (HPC-L) 湿打処方 WG Tablets MX-1 3% MX-1 5% MX-1 6% DC-1 直打処方 Tablets Only 5% MX-1 demonstrates the same 6 sustained release profile of SSA from 4 DC tablets as the WG tablets, however HPC could not sustain release of SSA 2 even at 12%. 溶出率 時間 [min] WG Tablets 湿打処方 HPC-L 3% HPC-L 6% HPC-L 9% HPC-L 12% 11
12 The Influence of Different Test Media - Highly Water Soluble Drug - 1 ph Buffer Buffer ph 1.2 ph Buffer Buffer ph DC-1 Tablets WG Tablets DC-2 Tablets (5% MX-1) DC-2 Tablets (12% HPC-L) DC-1 Tablets WG Tablets DC-2 Tablets (5% MX-1) DC-2 Tablets (12% HPC-L) Water DC-1 Tablets WG Tablets DC-2 Tablets (5% MX-1) DC-2 Tablets (12% HPC-L) MX-1 could adjust the dissolution profile of DC tablets in different test media to that of WG tablets
13 The Influence of Different Rotating Speeds - Highly Water Soluble Drug - DC-2 Tablets (5% MX-1) 溶出率 [%] WG Tablets 1rpm 5rpm ph Buffer 1.2 湿打処方 /1rpm 湿打処方 /5rpm rpm 5rpm 時間 [min] MX-1 shows the same dissolution profile as WG tablets at both conditions of 5 rpm and 1 rpm. 溶出率 [%] DC-2 Tablets (12% HPC-L) 1rpm 5rpm 湿打処方 /1rpm 湿打処方 /5rpm HPC-L 12% 5r HPC-L 12% 時間 [min] 13
14 Disintegration of Tablets - Highly Water Soluble Drug Water DC-1 Tablets WG Tablets DC-2 Tablets (5% MX-1) Disintegration Time [min] DC-2 Tablets (12% HPC-L) MX-1 could sustain release of SSA from DC tablets without delaying the disintegration time compared to WG tablets. 14
15 Experiment Procedure - Water Insoluble Drug - WG method Etz 1 Lactose 2 HPC-L 3 3 wt% 7 wt% 5 wt%* (*Of total of above) 1 Ethenzamide, Yoshitomi (Solubility in water:.97 mg/ml) 2 Pharmatose 2M, DMV-Fonterra 3 Hydroxypropyl cellulose, Type L Granulation High shear granulator VG-1 (Powrex Corporation), Load: 15g, Water: 14g, Impeller: 28rpm, Cross screw: 3rpm, Granulation time: 3min Drying Fluidized bed granulator MP-1 (Powrex Corporation) Granule Tableting Evaluation COMIL (Powrex Corporation), Screen: 1.14mmφ, Spacer: 25mm, Frequency: 4Hz, - 141μm Single press (MODEL-1321DW CREEP, AIKOH Engineering) 18 mg, φ8 mm, round-face (Tablet hardness: about 6N) -Dissolution test Rotating paddle (5 rpm) method with 9 ml medium, Water, Artificial gastric buffer ph 1.2 (1st fluid in JP XIV), Artificial intestinal buffer ph 6.8 (2nd fluid in JP XIV) and buffer ph 4. 15
16 Experiment Procedure - Water Insoluble Drug - DC-1 method DC-2 method Etz 1 Lactose 2 MCC 3 3 wt% 5 wt% 2 wt% Etz 1 Lactose 2 MCC 3 MX-1 or HPC-L 4 3 wt% wt% 2 wt% 6-15 wt% 1 Ethenzamide, Yoshitomi 2 Super-Tab TM, DMV-Fonterra 3 Microcrystalline cellulose, Ceolus UF-711, ASAHI KASEI 4 Hydroxypropyl cellulose, Type L Mixing for 3 min in PE bag Tableting Single press (MODEL-1321DW CREEP, AIKOH Engineering) 18 mg, φ8 mm, round-face (Tablet hardness: about 6N) Evaluation -Dissolution test Rotating paddle (5 rpm) method with 9 ml medium, Artificial gastric buffer ph 1.2 (1st fluid in JP XIV) 16
17 Dissolution Profiles from WG Tablets and DC Tablets - Water Insoluble Drug - 1 DC-1 Tablets ph buffer DC-2 Tablets Method (MX-1) WG Tablets DC-2 Tablets (HPC-L) MX 1:6% MX 1:8% Only 8% MX-1 demonstrates the same 6 sustained release profile of Etz from DC 4 tablets as the WG tablets, however HPC could not sustain the release of 2 Etz even at 15% HPC-L:1% HPC-L:15% 17
18 The Influence of Different Test Media on WG Tablets - Water Insoluble Drug WG (ph 1.2) WG (ph 6.8) WG (water) WG Tablets The dissolution profiles of WG tablets in ph buffer 6.8 and water show the biggest difference. Dissolution tests of DC tablets with either 5% MX-1 or 5% HPC were performed in ph buffer 6.8 and water. 18
19 The Influence of Different Test Media on DC Tablets - Water Insoluble Drug - WG tablet DC tablets with either 5% MX-1 or 5% HPC-L Etz 1 Lactose 2 HPC-L 3 3 wt% 7 wt% 5 wt%* (*Of total of above) Etz 1 Lactose 4 MX-1 or HPC-L 3 3 wt% 7 wt% 5 wt%* (*Of total of above) 1 Ethenzamide, Yoshitomi 2 Pharmatose 2M, DMV-Fonterra 3 Hydroxypropyl cellulose, Type L 4 Super-Tab TM, DMV-Fonterra WG Tablets DC Tablets (5% HPC-L) DC Tablets (5% MX-1) WG (ph 6.8) WG (water) DC with 5% HPC (ph 6.8) DC with 5% HPC (water) DC with 5% MX-1 (ph 6.8) DC with 5% MX-1 (water) Both WG tablets and DC tablets which contain 5% HPC showed faster dissolution in ph buffer 6.8 than in water. To the contrary, DC tablets which contain MX-1 showed the reverse action. Therefore HPC was used in order to enhance the dissolution in ph buffer 6.8 together with a main matrix agent, MX-1. 19
20 The Influence of Different Test Media on DC Tablets - Water Insoluble Drug - WG tablet DC tablets with 5% MX-1 and 5% HPC-L Etz 1 Lactose 2 HPC-L 3 3 wt% 7 wt% 5 wt%* (*Of total of above) Etz 1 Lactose 4 MCC 5 MX-1 HPC-L 3 3 wt% 4 wt% 2 wt% 5 wt% 5 wt% 1 Ethenzamide, Yoshitomi 2 Pharmatose 2M, DMV-Fonterra 3 Hydroxypropyl cellulose, Type L 4 Super-Tab TM, DMV-Fonterra 5 Microcrystalline cellulose, Ceolus UF-711, ASAHI KASEI 1 8 ph buffer Water 6 4 WG 6 4 WG 2 DC with 5% MX-1 + 5% HPC-L DC with 5% MX-1 + 5% HPC-L By using 5% MX-1 and 5% HPC, the dissolution profiles are closer to that of WG tablets, but not the same. It needs to be promoted in the later stage of the dissolution. 2
21 The Effect of PEG on Drug Release Profile - Water Insoluble Drug - DC tablets with 5% MX-1 and 5% HPC-L and 1% PEG Etz 1 Lactose 2 MCC 3 MX-1 HPC-L 4 PEG 5 3 wt% 3 wt% 2 wt% 5 wt% 5 wt% 1 wt% 1 Ethenzamide, Yoshitomi 2 Super-Tab TM, DMV-Fonterra 3 Microcrystalline cellulose, Ceolus UF-711, ASAHI KASEI 4 Hydroxypropyl cellulose, Type L 5 Polyethylene glycol, Macrogol 6, Sanyo 1 8 Buffer ph buffer ph Water %MX-1+5%HPC 5%MX-1+5%HPC+1%PEG %MX-1+5%HPC 5%MX-1+5%HPC+1%PEG By adding 1% PEG, the dissolution was restrained in the early stage and then it was promoted in the later stage. 21
22 Experiment Procedure - Water Insoluble Drug - DC-3 method Etz 1 Lactose 2 MCC 3 MX-1 HPC-L 4 PEG 5 3 wt% 3 or 33 wt% 2 wt% 5 wt% 5 wt% 7 or 1 wt% 1 Ethenzamide, Yoshitomi 2 Super-Tab TM, DMV-Fonterra 3 Microcrystalline cellulose, Ceolus UF-711, ASAHI KASEI 4 Hydroxypropyl cellulose, Type L 5 Polyethylene glycol, Macrogol 6, Sanyo Mixing for 3 min in PE bag.5% Mg-St 6 6 Magnesium Stearate, Taihei Chemical Industrial Co. Ltd. Tableting Rotary Press (Clean Press, Kikusui Seisakusho Ltd.), 12punches, 54rpm 18 mg, φ8 mm, round-face Evaluation -Dissolution test Rotating paddle (5 rpm) method with 9 ml media, Water, Artificial gastric buffer ph 1.2 (1st fluid in JP XIV), Artificial intestinal buffer ph 6.8 (2nd fluid in JP XIV) and Buffer ph 4. 22
23 Dissolution Profiles in Different Media - Water Insoluble Drug Water WG Tablets DC-1 Tablets DC-3 Tablets (7% PEG) DC-3 Tablets (1% PEG) It was possible to adjust the dissolution profile of DC tablets in different test media by using 5% MX-1 in combination with 5% HPC and 7-1% PEG to that of WG tablets. MX-1 acted as a sustained-release matrix and PEG was used to specifically control the dissolution profile. HPC was effective to enhance the dissolution in ph buffer 6.8, in which the WG tablet shows faster dissolution than in the other media Buffer ph Buffer ph Buffer ph Buffer ph Buffer ph Buffer ph
24 Disintegration of Tablets - Water Insoluble Drug Water DC-1 Tablets WG Tablets DC-3 Tablets (7% PEG) DC-3 Tablets (1% PEG) Disintegration Time [min] MX-1 could sustain release of Etz from DC tablets without delaying disintegration time compared to WG tablets. 24
25 Storage Stability of Drug Release under Accelerated Conditions - Water Insoluble Drug - Etz/Lactose/MCC/MX-1/HPC/PEG =3/33/2/5/5/7 Storage for 6 months under the condition of 4 C75%R.H. in sealed glass bottles 1 Water 1 ph Buffer Buffer ph 1.2 ph Buffer Buffer ph 6.8 Buffer ph Buffer ph 溶出率 [%] 6 4 溶出率 [%] 6 4 溶出率 [%] 6 4 溶出率 [%] 純水 4 75%RHオープン 時間 [min] 時間 [min] 時間 [min] 時間 [min] 8 WG Tablets-initial 湿打 -initial 直打 DC-3 -initial Tablets (7% 6 PEG)-initial 直打 -2week 直打 -1month 溶出率 [%] DC-3 Tablets (7% PEG)-2 weeks 4 DC-3 Tablets (7% PEG)-1 month 直打 DC-3-3month Tablets (7% 2 PEG)-3 months DC-3 Tablets (7% PEG)-6 months 直打 -6month 時間 [min] The release profiles of Etz from DC-3 tablets with 7% PEG hardly changed under accelerated conditions for 6 months. 25
26 Storage Stability of Drug Release under Accelerated Conditions - Water Insoluble Drug - Etz/Lactose/MCC/MX-1/HPC/PEG =3/3/2/5/5/1 Storage for 6 months under the condition of 4 C75%R.H. in sealed glass bottles 1 Water 1 ph Buffer Buffer ph 1.2 ph Buffer Buffer ph 6.8 ph Buffer Buffer ph 溶出率 [%] 6 4 溶出率 [%] 6 4 溶出率 [%] 6 4 溶出率 [%] 純水 4 75%RH オープン 時間 [min] 1 時間 [min] 時間 [min] 時間 [min] 湿打 -initial 直打 -initial 直打 -2week 直打 -1month 直打 -3month 直打 -6month 溶出率 [%] 8 WG Tablets-initial DC-3 Tablets (7% PEG)-initial 6 DC-3 Tablets (7% PEG)-2 weeks 4 DC-3 Tablets (7% PEG)-1 month DC-3 Tablets (7% PEG)-3 months 2 DC-3 Tablets (7% PEG)-6 months 時間 [min] The release profiles of Etz from DC-3 tablets with 1% PEG hardly changed under accelerated conditions for 6 months. 26
27 How could SWELSTAR TM MX-1 Specifically Control the Dissolution Profile? In combination with PEG, MX-1 could restrain the dissolution of the DC tablets in the early stage and then promote dissolution in the later stage. The mechanism of the dissolution control by MX-1 and PEG was investigated. 27
28 Experiment Procedure - The Effect of PEG - APAP 1 MX-1 or HPMC 2 MCC 3 PEG 4 1 wt% 6 wt% 2-3 wt% -1 wt% 1 Acetaminophen, Yoshitomi (Solubility in water: 15.8 mg/ml) 2 Hydroxypropyl methylcellulose, Viscosity of 2% solution: 1mpa s 3 Microcrystalline cellulose, Ceolus KG-82, ASAHI 4 Polyethylene glycol, Macrogol 6, Sanyo Mixing for 3 min in PE bag Tableting Single press (MODEL-1321DW CREEP, AIKOH Engineering) 18 mg, φ8 mm, round-face, Compression force 6 kn Evaluation -Dissolution test Rotating basket (1 rpm) method with 9 ml medium Artificial intestinal buffer (2nd fluid in JP XIV), ph: 6.8, α-amylase 5 μg/l -Tablet weight & water absorbing capacity (WAC) Tablet being removed during dissolution test WAC= (TW wet TW dry ) / TW dry 1 TW wet : Tablet weight in wet state TW dry : Tablet weight after drying 28
29 Dissolution Profiles of Matrix Tablets - The Effect of PEG - 1 6% MX-1 6% HPMC 1 % Dissolution 8 Dissolution rate [%] PEG(%) Time (hr) % Dissolution Dissolution rate [%] PEG(%) Time (hr) In combination with 1% PEG, MX-1 restrained the dissolution of matrix tablets in the early stage and then promoted dissolution in the later stage, whereas HPMC showed no change of the dissolution with PEG. 29
30 Swelling and Erosion of Matrix Tablets during Drug Dissolution - The Effect of PEG - Tablet weight Wet weight in wet (mg) state [mg] Tablet weight in wet state swelling MX-1 PEG % MX-1 PEG1% HPMC PEG % HPMC PEG1% erosion Time(hr) [hr] Water Water absorbing capacity(%) [%] Water absorbing capacity MX-1 PEG % MX-1 PEG1% HPMC PEG % HPMC PEG1% Time Time(hr) [hr] Both MX-1 and HPMC swelled in the first 2 hours, and then eroded. Tablet weight in wet state showed that MX-1 experienced less erosion than HPMC especially without PEG. Addition of PEG increased water absorbing capacity and accelerated erosion for MX-1 after 5 hours. PEG did not affect swelling or erosion patterns of HPMC. 3
31 Assumed Mechanism: How could SWELSTAR TM MX-1 Specifically Control the Dissolution Profile with PEG? 6% MX-1 Matrix Tablet 1st stage Hydration of MX-1 particles was promoted, then strong gel layer was formed. Drug diffusion was restrained effectively. 2nd stage Excess water absorption decreases gel strength. Diffusion of drugs and erosion of gel layer were promoted remarkably. Water penetration was promoted by adding PEG Dissolution % Dissolution rate [%] st stage 2nd stage PEG: % PEG: 1 % 2 Time 4 [hr] Time (hr) 1 6% HPMC Hydration of HPMC particles was not largely affected by promoting water penetration, because hydration rate was very high originally. Dissolution % Dissolution rate [%] PEG: % PEG: 1 % Matrix Tablet Time (hr) Time [hr] 31
32 Assumed Mechanism: How could SWELSTAR TM MX-1 Sustain Release of Drug without Delaying Disintegration Time? 5% MX-1 Gel Layer Water Penetration Tablet Swelling Disintegration It is assumed that tablets containing 5% MX-1 disintegrate into fragments, and each fragment forms gel layer ( ) on its surface, which sustains the release of drug. 32
33 CONCLUSIONS MX-1 can sustain the release of drugs from DC tablets at low doses without delaying disintegration time, and adjust the dissolution profile to the original dissolution profile of WG tablets in combination with other excipients such as PEG. MX-1 is a sustained-release excipient which is applicable to varying conditions such as drugs with different water solubilities, various media with different ph and different rotation speeds. Tablets containing MX-1 show stable drug release profiles under accelerated conditions. MX-1 can perform as an effective and useful sustained-release excipient to control dissolution profiles of DC tablets. 33
34 Thank you for your attention! 34
DVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa, NJ
QbD Approach to Formulation of Hydrophilic Matrix Using Sample Kit of Hypromellose [Metolose SR] DVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa,
More informationHydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-069-1 (Supersedes PTR-069) Page 1 of 8 Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Abstract Summary. Introduction. Experimental Methods. Consumer Specialties ashland.com
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-037-3 (Supersedes PTR-037-2) Page 1 of 7 Hydrodynamic Robustness of Hypromellose and Hydroxypropyl Cellulose Based Modified Release
More informationCONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications
Hypromellose CONTENTS PAGE 2 Preface Matrix system Selection of METOLOSE grades Specifications Properties Powder Solution Application Related Patents 3 4-5 6 8 10 13 14 17 Please note: The information
More informationThe Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation
METHOCEL Premium Cellulose Ethers Application Data The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation INTRODUCTION Hydrophilic matrices
More informationContinuous Granulation Using a Twin-Screw Extruder. Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016
Continuous Granulation Using a Twin-Screw Extruder Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016 What is a twin screw extruder and how to use it for continuous granulation? Dry feed:
More informationDESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN
Int. J. Chem. Sci.: 10(4), 2012, 2199-2208 ISSN 0972-768X www.sadgurupublications.com DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN K. V. R. N. S. RAMESH *, B. HEMA KIRNAMAYI
More informationThe Particle Design of Cellulose and the Other Excipients for a Directly Compressible Filler-Binder
The Particle Design of Cellulose and the Other Excipients for a Directly Compressible Filler-Binder Hiroto Miyamoto KNOWKATSU 1 Abstract Cellulose and saccharide are commonly used filler-binder. This summary
More informationFormulation and Evaluation
Chapter-5 Formulation and Evaluation 5.1 OBJECTIVE After successful taste masking and solubility enhancement of drugs in preliminary studies, by using Mannitol Solid Dispersion, next step includes the
More informationApplication of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products
57. Starch Convention, Detmold, April 26-28, 2006 K.-J. Steffens Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products Starches, Pharmaceutical Applications _ Starches
More informationCritical material properties for the design of robust drug products : excipient functionality related characteristics
Critical material properties for the design of robust drug products : excipient functionality related characteristics Dr Liz Meehan, Pharmaceutical Development, Macclesfield UK 1 Excipients Definition
More informationEffect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media
Effect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media Sandip B. Tiwari, Ph.D. Technical Director: South Asia Colorcon Asia Pvt. Ltd., Goa, India DISSO-INDIA 2013, May
More informationBiopharmaceutics Dosage form factors influencing bioavailability Lec:5
Biopharmaceutics Dosage form factors influencing bioavailability Lec:5 Ali Y Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of Pharmacy University of Sulaimani 09/01/2019
More informationPHARMACEUTICAL AID PREPARED BY B.KIRUTHIGA LECTURER DEPT OF PHARMACEUTICAL CHEMISTRY
PHARMACEUTICAL AID PREPARED BY B.KIRUTHIGA LECTURER DEPT OF PHARMACEUTICAL CHEMISTRY Excipients are inactive ingredients used as carriers for the active ingredients in a pharmaceutical product. These may
More informationTable 1 Hydrophilicity of MC and HPMC Grades. Polymer Cloud Point ( C) Hydrophilicity MC HPMC Type 2910 HPMC Type
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-046-1 (Supersedes PTR-046) Page 1 of 6 Effect of Hypromellose and Methylcellulose Substitution Type, Molecular Weight and Drug Solubility
More informationFLORITER. New Technology for Innovative Formulation Design.
FLORITER New Technology for Innovative Formulation Design www.tomitaph.co.jp FLORITE Dramatically Change Your Formulation FLORITE is synthetic Calcium Silicate with exceptional liquid absorbency and excellent
More informationTo study the effect that hydroxypropylcellulose (HPC) polymer molecular weight (MW) exerts on drug release rates and mechanism from matrix tablets.
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-029-1 (Supersedes PTR 029) Page 1 of 7 Hydroxypropylcellulose in Modified Release Matrix Systems: Polymer Molecular Weight Controls
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-8 Page 1 of 6 Are Cellulosic Controlled Release Technologies Vulnerable to Dose Dumping in Ethanolic Dissolution Media? Elanor Pinto,
More informationFORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD
Int. J. Chem. Sci.: 6(3), 2008, 1270-1275 FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD K. P. R. CHOWDARY, P. TRIPURA SUNDARI and K. SURYA
More informationTECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations
TECHNICAL INFORMATION 1426 RxCIPIENTS FM 1 A versatile excipient for orally disintegrating tablet (ODT) formulations Table of contents 1 Introduction 3 2 Mode of action and advantages of RxCIPIENTS FM
More informationGraphical Abstract. Final Step. Iwao et al. First Step Disintegrant. Second Step. Available surface area (St) using the data of dissolution study
Graphical Abstract First Step Disintegrant Iwao et al. Second Step Available surface area (St) using the data of dissolution study t b F( t) 1 exp ( t / a) C /( C W / V ) df( t) dt S( t) V / k ln s s 0
More informationThe unlocked synergy of DFE Pharma MCC
The unlocked synergy of DFE Pharma MCC We are DFE Pharma We are the global leader in excipient solutions. We develop, produce and market excipients for oral solid dose and dry powder inhalation formulations.
More informationPharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency
Pharma & Food Solutions POLYOX TM Water Soluble Resins Combining Flexibility with Consistency POLYOX 9-13 POLYOX 9-13 POLYOX * are nonionic poly (ethylene oxide) polymers that meet all the specifications
More informationWettable Magnesium Stearate. What Are Customers Looking for in Selecting Pharmaceutical Lubricants?
Wettable Magnesium Stearate Presented By: Richard Pudlo P.E. Principal Chemical Engineer April 29 th, 2015 What Are Customers Looking for in Selecting Pharmaceutical Lubricants? Meet USP/.NF monograph
More informationCHAPTER 8 HYDROGEL PLUG FORMULATION AND EVAUATION
CHAPTER 8 HYDROGEL PLUG FORMULATION AND EVAUATION 8.1 Preparation of erodible tablet plug (Hydrogel Plug) Direct compression method was used to prepare the erodible tablet plug. The compositions of different
More informationSTUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS
Int. J. Chem. Sci.: 10(4), 2012, 1934-1942 ISSN 0972-768X www.sadgurupublications.com STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS K. VENUGOPAL * and K. P. R. CHOWDARY a Nirmala College
More informationA Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac
Asian Journal of Chemistry Vol. 22, No. 6 (2010), 4239-4244 A Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac K.P.R. CHOWDARY*
More informationFormulation and Development of Sustained Release Tablets of Valsartan Sodium
INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY, BIOLOGY AND CHEMISTRY Research Article Formulation and Development of Sustained Release Tablets of Valsartan Sodium G. Sandeep * and A. Navya Department of
More informationVIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies
VIVAPHARM PVP/VA Copovidone, Ph.Eur. USP/NF, JPE, E 1208, FCC The Ultimate Tablet Binder for All Processing Technologies Direct Compression Dry Granulation Hot Melt Extrusion Wet Granulation VIVAPHARM
More informationDirect Compression. With the right ingredients it s a simple, cost-effective manufacturing process
Direct With the right ingredients it s a simple, cost-effective manufacturing process TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow Speed and savings sounds good to us
More informationFORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS
International Journal of PharmTech Research CODEN( USA): IJPRIF ISSN : 0974-4304 Vol.1, No.3, pp 634-638, July-Sept 2009 FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS K. Reeta Vijaya
More informationSTARCH Application Data
STARCH 1500 Application Data Partially Pregelatinized Maize Starch Starch 1500, Partially Pregelatinized Maize Starch, Used as a Binder Disintegrant in High Shear Wet Granulation Comparison to Povidone
More informationSUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING
SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING Dr. Dieter Lubda MilliporeSigma is a business of Merck KGaA, Darmstadt, Germany Agenda: Sustained release
More information7. SUMMARY, CONCLUSION AND RECOMMENDATIONS
211 7. SUMMARY, CONCLUSION AND RECOMMENDATIONS Drug absorption from the gastro intestinal tract can be limited by various factors with the most common one being poor aqueous solubility and poor permeability
More informationTechnical brochure StarLac
T R TABLETING AC DIRECT COMPRESSION CO-PROCESSED LACTOSE Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture is
More informationOffice europeen des brevets. Publication number: Applicant: Chugai Seiyaku Kabushiki Kaisha 5-1, 5-chome, Ukima Kita-ku Tokyo(JP)
J Europaisches Patentamt European Patent Office Publication number: 0 2 932 Office europeen des brevets A2 EUROPEAN PATENT APPLICATION Application number: 87100549.2 Date of filing: 16.01.87 int. Ci.
More informationFormulation and evaluation of oro-dispersible tablets of lafutidine
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (5):226-235 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationSTARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant
EXCIPIENTS STARCH 1500 Proven and Trusted Excipient for Performance and Versatility Effective and economical disintegrant Excellent stability for moisture sensitive drugs Manufactured exclusively for the
More informationThe binding performance of DFE Pharma Starch
The binding performance of DFE Pharma Starch MCC Starch Lactose Inhalation Superdisintegrants We are DFE Pharma We are the global leader in excipient solutions. We develop, produce and market excipients
More informationExcipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical
Excipient Quality & Trouble Shooting By Seema Trivedi GM, Technical Back Ground The Society for Pharmaceutical Dissolution Science (SPDS) had held its 6th Annual International Convention Disso India -
More informationAsian Journal of Pharmacy and Life Science ISSN Vol. 2 (2), July-Sept,2012
STUDIES ON EFFECT OF SUPERDISINTEGRANTS ON ETORICOXIB TABLET FORMULATIONS Chowdary K. P. R 1, Venugopal. K *2 1 College of Pharmaceutical Sciences, Andhra University, Vishakapattanam. 2 * Nirmala college
More informationStudies of Rapidly Disintegrating Tablets in the Oral Cavity Using Co-ground Mixtures of Mannitol with Crospovidone
February 2002 Chem. Pharm. Bull. 50(2) 193 198 (2002) 193 Studies of Rapidly Disintegrating Tablets in the Oral Cavity Using Co-ground Mixtures of Mannitol with Crospovidone Toshifusa SHU,* Hideshi SUZUKI,
More informationRe-compaction properties of lactose and microcrystalline cellulose
Re-compaction properties of lactose and microcrystalline cellulose Individual excipients MCC Starch Lactose Inhalation Superdisintegrants SuperTab 21AN (anhydrous lactose) is the preferred form of lactose
More informationFormulation Study for Lansoprazole Fast-disintegrating Tablet. II. Effect of Triethyl Citrate on the Quality of the Products
September 2003 Chem. Pharm. Bull. 51(9) 1029 1035 (2003) 1029 Formulation Study for Lansoprazole Fast-disintegrating Tablet. II. Effect of Triethyl Citrate on the Quality of the Products Toshihiro SHIMIZU,*
More informationLubriTose Mannitol Michael Crowley, Director of R&D, Excipients
LubriTose Mannitol Michael Crowley, Director of R&D, Excipients Introduction Michael Crowley Director of R&D Excipients 158 St. Highway 320 Norwich, NY 13815 PH 315-802-5970 Michael.Crowley@Kerry.com 2
More informationInvestigation of physicochemical drug properties to prepare fine globular. granules composed of only drug substance in fluidized bed rotor granulation
Mise R. et al., Page 1 1 2 Chem. Pharm. Bull. Note 3 4 5 Investigation of physicochemical drug properties to prepare fine globular granules composed of only drug substance in fluidized bed rotor granulation
More informationTechnical brochure CombiLac
OM I AC TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture is
More informationRESEARCH ARTICLE. Khemchand Gupta, S.B. Roy, Indrajeet Singhvi
RESEARCH ARTICLE ISSN: 2348-8948 Vol: 3; Issue: 6 PREFORMULATION STUDY IN THE DEVELOPMENT OF A TABLET FORMULATION FOR THE TREATMENT OF ULCERATIVE COLITIS Khemchand Gupta, S.B. Roy, Indrajeet Singhvi Pacific
More informationInt. Res J Pharm. App Sci., 2014; 4(1):47-51 ISSN:
International Research Journal of Pharmaceutical and Applied Sciences (IRJPAS) Available online at www.irjpas.com Int. Res J Pharm. App Sci., 2014; 4(1):47-51 Research Article FORMULATION AND EVALUATION
More informationMETOLOSE: CONTENTS PAGE
METOLOSE: CONTENTS PAGE 2 Preface What is Metolose Substitution types Specifications 1) Available grades & viscosity 2) Nomenclature 3) Packaging Characteristics of Metolose Properties of Metolose 1) Powder
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article FORMULATION DEVELOPMENT AND EVALUATION OF IMMEDIATE RELEASE BILAYER TABLETS OF TELMISERTAN AND HYDROCHLOROTHIAZIDE
More informationFormulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium
Available online on www.ijddt.com International Journal of Drug Delivery Technology 214; (3); 98-13 Research Article ISSN: 97 441 Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast
More informationThe Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices
METHOCEL Application Data Premium Cellulose Ethers The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices ABSTRACT SUMMARY This
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationEP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/42
(19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 8 36 A1 (43) Date of publication: 14..09 Bulletin 09/42 (21) Application number: 084239.1 (1) Int Cl.: A61K 9/16 (06.01) A61K 9/ (06.01) A61K 31/4178 (06.01)
More informationJournal of Chemical and Pharmaceutical Research
Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 211, 3(2):786-791 Development and optimization of colon targeted
More informationFormulation and evaluation of immediate release salbutamol sulphate
5 Formulation, optimization and evaluation of immediate release layer of salbutamol sulphate Salbutamol is moderately selective beta (2)-receptor agonist similar in structure to terbutaline and widely
More informationOPTIMIZATION OF CONTROLLED RELEASE GASTRORETENTIVE BUOYANT TABLET WITH XANTHAN GUM AND POLYOX WSR 1105
Digest Journal of Nanomaterials and Biostructures Vol. 9, No. 3, July September 2014, p. 1077-1084 OPTIMIZATION OF CONTROLLED RELEASE GASTRORETENTIVE BUOYANT TABLET WITH XANTHAN GUM AND POLYOX WSR 1105
More informationResearch Article Formulation and Evaluation of Dual Component Tablets of Metoprolol tartrate
Research Article Formulation and Evaluation of Dual Component Tablets of Metoprolol tartrate Rashmin N. Patel 1 * and Praful D. Bharadia 2 Department of Pharmaceutics, B. S. Patel Pharmacy College, Saffrony
More informationFormulation Development of Aceclofenac Tablets Employing Starch Phosphate -A New Modified Starch
Abstract K.P.R. Chowdary et al. / International Journal of Pharma Sciences and Research (IJPSR) Formulation Development of Aceclofenac Tablets Employing Starch Phosphate -A New Modified Starch K.P.R. Chowdary*,
More informationGuidance on Pharmaceutical Excipient Suitability Studies (PESS) with Chinese Pharmacopeia (Volume 4): Basics and Examples
Guidance on Pharmaceutical Excipient Suitability Studies (PESS) with Chinese Pharmacopeia (Volume 4): Basics and Examples Professor Jiasheng Tu, Ph. D. France 2018/09 content 1 Introduction 2 PESS guidance
More informationCo-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009
Co-Processed Excipients: Regulatory Challenges Carl Mroz Colorcon Limited June 2009 What is a Co-Processed excipient? Several types of excipient contain multiple components by design Use of processing
More informationTABLET DESIGN AND FORMULATION
TABLET DESIGN AND FORMULATION PART 5 Industrial pharmacy 5th class 1st semester TABLET DESIGN AND FORMULATION Conventional oral tablets for ingestion usually contain the same classes of components in addition
More informationMODULATION OF GASTROINTESTINAL TRANSIT TIME OF SALBUTAMOL SULPHATE BY FLOATING APPROCHES
Pooja et al Journal of Drug Delivery & Therapeutics; 213, 3(3), 37-41 37 Available online at http://jddtonline.info RESEARCH ARTICLE MODULATION OF GASTROINTESTINAL TRANSIT TIME OF SALBUTAMOL SULPHATE BY
More informationSTABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS
Int. J. Chem. Sci.: 8(1), 2010, 405-414 STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS V. L. NARASAIAH, T. KARTHIK KUMAR, D. SRINIVAS, K. SOWMYA, P. L. PRAVALLIKA and Sk. Md. MOBEEN
More informationDevelopment of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System
Opadry Enteric Application Data Acrylic-Based Coating System Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System INTRODUCTION Acetylsalicylic acid (aspirin)
More informationFormulation and Evaluation of Gastroretentive Dosage form of Ciprofloxacin Hydrochloride.
Available online on www.ijcpr.com International Journal of Current Pharmaceutical Review and Research, 3(4), 105-109 Research Article ISSN: 0976-822X Formulation and Evaluation of Gastroretentive Dosage
More informationSCIENTIFIC DISCUSSION. Efavirenz
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredient (API): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Rifampicin/Isoniazid 150mg/75mg filmcoated Tablets Svizera
More informationAnyCoat. From Nature, Beside you.
AnyCoat From Nature, Beside you www.lotte-cellulose.com 04 AnyCoat is 05 Certificates of AnyCoat AnyCoat-C 06 General Characteristics 07 Specifications 08 Chemical Structure, Nomenclature 09 Functional
More informationPREPARATION AND EVALUATION OF STARCH - PEG 1500 CO-PROCESSED EXCIPIENT AS A NEW DIRECTLY COMPRESSIBLE VEHICLE IN TABLET FORMULATIONS
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article PREPARATION AND EVALUATION OF STARCH - PEG 1500 CO-PROCESSED EXCIPIENT AS A NEW DIRECTLY COMPRESSIBLE
More informationTable 1. Coating Parameters
ACRYL-EZE Aqueous Acrylic Enteric System Application Data Performance Characteristics of Acryl-EZE, Aqueous Acrylic Enteric System Eudragit L1-55 is a copolymer of methacrylic acid and ethyl acrylate (1:1
More informationGranulation Aggregation
Granulation Aggregation Wet granulation Solvent granulation (crust granules) Binder granulation (sticked granules) Granulation liquid Water Water + alcohol mixture Macromolecular colloidal solution i.e.:
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationB. Jayakar et. al. FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLET OF CELECOXIB R. Margret Chandira, Shyam Sharma, Debjit Bhowmik, B.
Page117 Online Available at www.thepharmaresearch.info THE PHARMA RESEARCH, A JOURNAL The Pharma Research (T. Ph. Res.), (2010), 4; 117-122. Published on- 15 Dec 2010 Copyright 2009 by Sudarshan Publication
More informationEFFECT OF SUPERDISINTEGRANTS ON RELEASE OF DOMPERIDONE FROM FAST DISSOLVING TABLETS
ISSN: 22-7346 B. Sujatha et al. / JGTPS/ 5(3)-(2014) 1973 1978 (Research Article) Journal of Global Trends in Pharmaceutical Sciences Journal home page: www.jgtps.com EFFECT OF SUPERDISINTEGRANTS ON RELEASE
More informationWHOPAR. SCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More information3. Drug or plant or excipients profile
3. Drug or plant or excipients profile 3. 1 Analysis of Reference Listed Drug (RLD) Product ABILIFY (aripiprazole) 3.1.1 Clinical The Reference Listed Drug (RLD) is Brand ABILIFY (aripiprazole) Tablets
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are
More informationEasy, fast and reliable!
Product Overview Easy, fast and reliable! Special easy-to-use preparations for film coating, sugar-coating, colouring and tabletting. s film coating products are one-step coating systems for pharmaceutical
More informationOCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100
IC OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE AC Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture
More informationFolic Acid in Human Nutrition
Folic Acid in Human Nutrition Folic acid is a water soluble B vitamin widely distributed in foods. Deficiencies lead to impaired cell division and altered protein synthesis. Newborn children of women receiving
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Research Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article FORMULATION AND EVALUATION OF BILAYERED FLOATING TABLETS OF METFORMIN HYDROCHLORIDE R.Margret Chandira*, P.Palanisamy,
More informationContent Uniformity of Direct Compression tablets
Content Uniformity of Direct Compression tablets Contents 1 Summary 4 2 Introduction 4 3 The role of drug particle size 4 4 The role of mixing strategy 5 5 The role of excipients 5 6 Laboratory data 6
More information1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small
Lecture-5 1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small intestine. Because the duodenum has the greatest
More informationDesign and In-vitro Evaluation of Silymarin Bilayer Tablets
CODEN (USA)-IJPRUR, e-issn: 2348-6465 International Journal of Pharma Research and Health Sciences Available online at www.pharmahealthsciences.net Original Article Design and In-vitro Evaluation of Silymarin
More informationKarnataka Department of Pharmaceutical Technology, H.K.E. Society s College of Pharmacy, Gulbarga, Karnataka ABSTRACT KEYWORDS:
335 P a g e International Standard Serial Number (ISSN): 2319-8141 International Journal of Universal Pharmacy and Bio Sciences 4(6): November-December 2015 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY
More informationLAB.2. Tablet Production Methods
LAB.2 Tablet Production Methods Dry methods Direct compression Dry granulation Wet methods Wet granulation Regardless whether tablets are made by direct compression or granulation, the first step, milling
More informationVolker Bühler. Pharmaceutical Technology of BASF Excipients. Pharma Ingredients &Services. Welcome to more opportunities.
Volker Bühler Pharmaceutical Technology of BASF Excipients Pharma Ingredients &Services. Welcome to more opportunities. Volker Bühler Pharmaceutical Technology of BASF Excipients 3 rd revised edition June
More informationPrimellose is an excellent choice as superdisintegrant in ODT applications
Primellose is an excellent choice as superdisintegrant in ODT applications MCC Starch Lactose Inhalation Superdisintegrants Summary In orally disintegrating tablets, the excipients of choice in direct
More informationInnovations in Pharmaceuticals and Pharmacotherapy.
Innovations in Pharmaceuticals and Pharmacotherapy www.innpharmacotherapy.com IPP eissn: 2321 323X Original Article Preformulation Studies for development of a generic capsule formulation of Celecoxib
More informationFormulation and Evaluation of Pulsatile Drug Delivery System of Rosuvastatin Calcium Using Different Swelling Polymers
ISSN: 2277-769 CODEN Code: PIHNBQ ZDB-Number: 266338-2 IC Journal No: 772 Vol. 1 No. 7 212 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION Formulation and Evaluation of Pulsatile Drug
More informationEP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/36
(19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 09 81 A1 (43) Date of publication: 02.09.09 Bulletin 09/36 (1) Int Cl.: A61K 9/ (06.01) A61K 31/436 (06.01) (21) Application number: 0838007.3 (22) Date
More informationFABRICATION AND EVALUATION OF GLIMEPIRIDE CORDIA DICHOTOMA G.FORST FRUIT MUCILAGE SUSTAINED RELEASE MATRIX TABLETS
Int. J. Chem. Sci.: 7(4), 2009, 2555-2560 FABRICATION AND EVALUATION OF GLIMEPIRIDE CORDIA DICHOTOMA G.FORST FRUIT MUCILAGE SUSTAINED RELEASE MATRIX TABLETS HINDUSTAN ABDUL AHAD *, B. PRADEEP KUMAR, C.
More informationVolume: 2: Issue-3: July-Sept ISSN FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF NICORANDIL
Volume: 2: Issue-3: July-Sept -2011 ISSN 0976-4550 FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF NICORANDIL Ajaykumar Patil*, Ashish Pohane, Ramya Darbar, Sharanya Koutika, Alekhya
More informationKollidon CL Kollidon CL-F Kollidon CL-SF Kollidon CL-M. Super-disintegrants and dissolution enhancers.
Kollidon CL Kollidon CL-F Kollidon CL-SF Kollidon CL-M Super-disintegrants and dissolution enhancers. 2 The Preface New: 4 dimensions of Kollidon CL standard, fine (CL-F), superfine (CL-SF) and micronized
More informationAdopting Technologies to Enhance Quality in Manufacturing
Adopting Technologies to Enhance Quality in Manufacturing Sandip B. Tiwari, Ph.D. March 18, 2012 Current Status of Quality in Pharma Manufacturing Pharmaceutical manufacturing techniques lag behind those
More informationCompression and Mechanical Properties of Tablet Formulations
Compression and Mechanical Properties of Tablet Formulations Containing Corn, Sweet, and Starches as Binders O.A. Odeku*, O.O. Awe, B. Popoola, M.A. Odeniyi, and O.A. Itiola The authors study the effects
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More information